LaKeith Stanfield and Ben Mendelsohn are set to topline Molepeople, an original horror thriller that pairs two genre forces: Blumhouse Atomic Monster and Paramount Primal. Paramount will distribute worldwide, and the film has been given a fixed theatrical date of Aug. 27, 2027.
The package
Rob Savage, who has Other Mommy opening this weekend, will direct from a script by Nathan Elston. The premise sends a man into abandoned tunnels beneath New York City, where he discovers a twisted society living under the streets.
- Co-financed and co-produced by Blumhouse Atomic Monster and Paramount Primal.
- Worldwide distribution: Paramount.
- Release date: Aug. 27, 2027.
- Production: late November or early December in the UK.
Producers are Jason Blum, J.D. Lifshitz, Raphael Margules and James Harris. Executive producers include Ryan Turek, Tracy Rosenblum, Elston and Savage.
Why the deal matters
The project was previously in development as an indie and moved to Paramount when Lifshitz and Margules set up Primal, their genre label. That is the real signal: studios are using focused genre banners to convert independent material into theatrical horror product, with known actors attached to widen the audience.
Stanfield arrives after Boots Riley’s I Love Boosters and Amazon’s Play Dirty; Mendelsohn after the Venice Film Festival premiere of Company. Their casting gives an original tunnel thriller the kind of recognition it would not otherwise command, while the 2027 date tells exhibitors Paramount is treating this as a theatrical event, not a streaming afterthought.
For media planners, that combination matters because star-led, original horror is cheaper to market than franchise fare but still carries talent-driven PR hooks. Blumhouse Atomic Monster’s pipeline gives the film a lean genre model, and Paramount Primal adds another financing lane. The late-August 2027 slot positions it as counter-programming in a summer window rather than as a year-end prestige play.
What to watch
The key test is whether a star-driven original horror title can open without known IP. Savage’s track record and the Blumhouse Atomic Monster model point to a contained production approach; the actors provide the marketing reach. If this works, expect more studio genre labels to package name casts around modest budgets and let the calendar do the heavy lifting.
Source: The Hollywood Reporter
